TP53 and myelodysplastic syndrome: When evaluating the 83 patients with MDS, only STAG2 (HR 2.7, 95% CI 1.11-6.57, p = 0.029) and TP53 (HR 5.19, 95% CI 2.05-13.12, p = 0.001) mutations impacted prognosis adversely, with TP53 mutations also predicting for shorter LFS (HR 8.96, 95% CI 2.10-38.12, p = 0.003).